RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas.
RVAC Medicines has raised $140.0M in total funding. The most recent round was Series B. The last funding was announced in April 2022.
RVAC Medicines's investors include Pavilion Capital, EDBI, C-Bridge Capital, GS Holdings.
RVAC Medicines is headquartered in Singapore, Singapore.
RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas.
RVAC Medicines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RVAC Medicines — Funding & Investors." VCBacked, April 26, 2022, https://www.vcbacked.co/company/rvac-medicines. Accessed August 14, 2026.
VCBacked. (2022). RVAC Medicines — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/rvac-medicines
{{cite web |title=RVAC Medicines — Funding & Investors |url=https://www.vcbacked.co/company/rvac-medicines |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated